Antibodies as Snakebite Antivenoms: Past and Future
Authors:
- Wilmar Dias da SilvaWSWilmar Dias da Silva
- Sonia A. De AndradeSASonia A. De Andrade
- Ângela Alice Amadeu MegaleÂMÂngela Alice Amadeu Megale
- Daniel Alexandre De SouzaDSDaniel Alexandre De Souza
- Osvaldo Augusto Sant’annaOSOsvaldo Augusto Sant’anna
- Fábio Carlos MagnoliFMFábio Carlos Magnoli
- Felipe Raimondi GuidolinFGFelipe Raimondi Guidolin
- Kemily Stephanie GodoiKGKemily Stephanie Godoi
- Lucas Yuri SaladiniLSLucas Yuri Saladini
- Patrick Jack SpencerPSPatrick Jack Spencer
- Fernanda Calheta Vieira PortaroFPFernanda Calheta Vieira Portaro
Open Access
Abstract
Snakebite envenomation is considered a neglected tropical disease, affecting tens of thousands of people each year. The recommended treatment is the use of antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms. In this review, the efforts made in the improvement of the already available antivenoms and the development of new antivenoms, focusing on snakes of medical importance from sub-Saharan Africa and Latin America, are described. Some antivenoms currently used are composed of whole IgGs, whereas others use F(ab’)2 fragments. The classic methods of attaining snake antivenoms are presented, in addition to new strategies to improve their effectiveness. Punctual changes in immunization protocols, in addition to the use of cross-reactivity between venoms from different snakes for the manufacture of more potent and widely used antivenoms, are presented. It is known that venoms are a complex mixture of components; however, advances in the field of antivenoms have shown that there are key toxins that, if effectively blocked, are capable of reversing the condition of in vivo envenomation. These studies provide an opportunity for the use of monoclonal antibodies in the development of new-generation antivenoms. Thus, monoclonal antibodies and their fragments are described as a possible alternative for the production of antivenoms, regardless of the venom. This review also highlights the challenges associated with their development.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/07467-1, 490048/2005-6, 2019/20832-7)
- National Council for Scientific and Technological Development (2013/07467-1, 490048/2005-6, 2019/20832-7)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/07467-1, 490048/2005-6, 2019/20832-7)
This publication has 91 references indexed in Scilit:
- Comparison of Phylogeny, Venom Composition and Neutralization by Antivenom in Diverse Species of Bothrops ComplexPLOS Neglected Tropical Diseases, 2013
- In Vivo Neutralization of α-Cobratoxin with High-Affinity Llama Single-Domain Antibodies (VHHs) and a VHH-Fc AntibodyPLOS ONE, 2013
- Humanized-Single Domain Antibodies (VH/VHH) that Bound Specifically to Naja kaouthia Phospholipase A2 and Neutralized the Enzymatic ActivityToxins, 2012
- Expression of Human Recombinant Antibody Fragments Capable of Partially Inhibiting the Phospholypase Activity ofCrotalus durissus terrificusVenomBasic & Clinical Pharmacology & Toxicology, 2009
- Coevolution of diet and prey-specific venom activity supports the role of selection in snake venom evolutionProceedings Of The Royal Society B-Biological Sciences, 2009
- The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and DeathsPLOS Medicine, 2008
- Venomous animals in Brazil: biology, clinic and therapeutics of envenomationsRevista do Instituto de Medicina Tropical de São Paulo, 2003
- Neutralizing Human Anti Crotoxin scFv Isolated from a Nonimmunized Phage LibraryScandinavian Journal of Immunology, 2000
- Preparation and characterization of β1-bungarotoxin bispecific monoclonal antibodyIUBMB Life, 1999
- Preliminary crystallographic study of the Fab fragment of a monoclonal antibody directed against a cobra cardiotoxinJournal of Molecular Biology, 1986